MK-677 (Ibutamoren) is a non-peptide, orally bioavailable (~60–70%) small molecule that acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a) in vitro, with a binding affinity (Ki) of approximately 0.4 nM. Its roughly 24-hour half-life produces sustained receptor engagement rather than the brief, pulsatile activation seen with short-acting injectable secretagogues – a pharmacokinetic profile relevant to the design of extended in vitro assay protocols. It is studied in laboratory settings as a tool compound for investigating ghrelin-receptor signalling, without the peptide-degradation issues that limit injectable secretagogues.

What is MK-677 from a research perspective?

MK-677 (also known by its developmental codes MK-0677 and L-163,191) originated from a Merck Research Laboratories medicinal chemistry program in the 1990s aimed at finding small molecules that could reproduce the growth hormone (GH)-releasing activity of peptide secretagogues without the stability limitations of a peptide backbone. The result was a spiroindoline-class compound: a non-peptide, orally active molecule engineered to bind the same receptor that peptide GH secretagogues activate, achieving oral bioavailability of approximately 60–70% in pharmacokinetic studies.

That receptor, the growth hormone secretagogue receptor (GHSR-1a), was itself identified and cloned through the same research effort, years before its endogenous ligand (the peptide hormone ghrelin) was isolated in 1999. MK-677 is therefore historically significant as one of the small-molecule tools that helped researchers characterize the GHSR-1a signalling pathway before ghrelin itself was even discovered.

Molecular characteristics

For researchers verifying compound identity against a Certificate of Analysis, MK-677’s core identifiers are:

• Chemical class: Spiroindoline, non-peptide small molecule
• CAS Number (free base): 159634-47-6
• CAS Number (mesylate salt): 159752-10-0
• Molecular formula (free base): C₂₇H₃₆N₄O₅S
• Molecular weight (free base): Approximately 528.66 g/mol
• PubChem CID: 178024 (free base) / 91903076 (mesylate salt)
• Oral bioavailability: Approximately 60–70%
• Biological half-life: Approximately 24 hours (supports once-daily dosing in research protocols)
• WADA status: Prohibited at all times, category S2.2 (growth hormone secretagogues and mimetics), in- and out-of-competition
• Synonyms: Ibutamoren, MK-0677, L-163,191

Structurally, MK-677 belongs to a spiroindoline scaffold rather than the peptide backbones used by earlier GH secretagogues like GHRP-6. This distinction is central to why it draws sustained research interest: a non-peptide small molecule is not subject to the same proteolytic degradation that limits peptide-based ligands in solution or in the gastrointestinal tract, which makes it a more chemically stable tool for extended in vitro assay work. Its approximately 24-hour half-life further distinguishes it pharmacokinetically from short-acting injectable secretagogues, allowing for once-daily dosing in research protocols where sustained receptor engagement is the variable of interest.

How does MK-677 behave in in vitro systems?

Receptor binding and potency

In the original characterisation work, MK-677 (then designated L-163,191) was shown to release growth hormone from cultured rat pituitary cells with an EC50 of approximately 1.3 nM: a potency in the same range as the peptide secretagogue GHRP-6 and the earlier nonpeptide secretagogue L-692,429. This functional EC50 is distinct from binding affinity: radioligand displacement studies have characterized MK-677’s binding affinity for GHSR-1a at a Ki of approximately 0.4 nM, a figure subsequently used as the reference benchmark against which newer GHSR-1a ligands are compared in receptor pharmacology literature.

Mechanistic basis

MK-677 activates GHSR-1a, which couples primarily with Gαq/11 proteins. Receptor activation triggers GDP-to-GTP exchange on the Gαq subunit, stimulating phospholipase C-beta (PLCβ). PLCβ hydrolyses membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases Ca²⁺ from endoplasmic reticulum stores, triggering GH vesicle exocytosis in somatotroph cells, while DAG activates protein kinase C (PKC), amplifying the secretory response. A secondary arm involves inhibition of inwardly rectifying K⁺ channels, causing membrane depolarisation and Ca²⁺ influx through voltage-gated channels. This calcium-flux readout was itself the assay system researchers used to originally identify and clone the receptor, and it remains a standard endpoint in in vitro pharmacology work involving GHSR-1a ligands. Separately, hypothalamic GHSR-1a activation is understood to suppress periventricular somatostatin release, lifting a tonic inhibitory brake on GH secretion.

Selectivity considerations

In vitro characterisation work has indicated that MK-677 releases GH through a pathway mechanistically distinct from growth hormone-releasing hormone (GHRH), meaning it does not act through the GHRH receptor. This distinction is one of the reasons GHSR-1a ligands are studied as a separate pharmacological category from GHRH-pathway compounds, despite both ultimately converging on GH secretion.

Tonic vs pulsatile activation: Research protocol implications

Unlike injectable GH secretagogues with short half-lives (ipamorelin and GHRP-6 are both generally cited in the range of one to two hours), MK-677’s approximately 24-hour half-life produces sustained receptor engagement rather than the discrete, short-lived stimulation typical of rapidly cleared ligands. Researchers designing assays where receptor activation duration is an independent variable should account for this distinction when selecting among GHSR-1a tool compounds.

More recent structural pharmacology

Cryo-electron microscopy structures of the human GHSR-Gi signalling complex bound to ibutamoren, published in 2021, provided atomic-resolution insight into how the compound occupies the receptor’s binding pocket alongside the endogenous ligand ghrelin. This structural work identified specific binding-pocket motifs relevant to receptor activation and continues to inform structure-activity relationship work on next-generation GHSR-1a ligands.

Why is MK-677 used as a research tool?

Non-peptide stability in assay systems

Because MK-677 is a small molecule rather than a peptide, it doesn’t require the cold-chain handling or rapid-degradation precautions that peptide-based GHSR-1a ligands do. This makes it a practical reference compound for in vitro pharmacology studies where consistent, stable ligand exposure across an assay timeline is important.

Receptor characterisation studies

Because MK-677 was part of the original toolkit used to identify and characterize GHSR-1a before ghrelin was discovered, it continues to appear in receptor pharmacology literature as a reference agonist – a benchmark compound against which newer GHSR-1a ligands, including ghrelin analogues, are compared in binding and functional assays.

Downstream pathway investigation

Beyond the pituitary, GHSR-1a has been detected in a range of other tissues, including the hypothalamus, adrenal and thyroid glands, heart, lung, kidney, and skeletal muscle. This broader receptor distribution has made MK-677 useful in cell-based studies exploring GHSR-1a signalling outside the classic somatotropic axis, including neuronal cell models examining receptor activity in the context of neurodegenerative disease pathways. Downstream of the pituitary, growth hormone released following GHSR-1a activation reaches hepatocytes via systemic circulation, where it engages GH receptors and initiates JAK2–STAT5b phosphorylation. Activated STAT5b drives IGF-1 gene transcription, producing the hepatic IGF-1 that serves as a key downstream signalling mediator of GH-axis activation. In in vitro studies, IGF-1 concentration is frequently used as a secondary endpoint to confirm upstream GH-axis activation by MK-677.

What does the research record show about safety signals?

In addition to its in vitro receptor pharmacology, the documented findings from MK-677’s clinical research program provide a relevant context for anyone designing protocols around this compound. In the foundational 1996 characterization by Chapman and colleagues, daily oral MK-677 at 25 mg increased mean 24-hour GH concentrations by approximately 97% in healthy elderly subjects, alongside a measurable increase in fasting glucose over four weeks: an early signal of the compound’s effect on glucose handling. Separately, a multicentre Phase IIb trial in elderly hip fracture patients was terminated early after a higher rate of congestive heart failure emerged in the MK-677 group (4 of 62 patients, 6.5%) compared to placebo (1 of 61, 1.7%), a signal the study authors attributed to GH-mediated fluid retention in a population with elevated baseline cardiovascular vulnerability. A separate, similarly designed hip-fracture trial did not identify a comparable cardiac signal, and the relatively small sample sizes involved limit how confidently either finding generalises. These findings, drawn from human clinical trials rather than in vitro work, are documented here because they represent a relevant safety context for researchers designing study protocols and exclusion criteria involving this compound.

What are the handling considerations for research use?

1. Handling precautions: MK-677 should be handled by trained laboratory personnel only, in a controlled environment. Use appropriate PPE and avoid direct skin contact or inhalation.
2. Storage: Store MK-677 powder at −20°C in a dry, dark environment, protected from light, heat, and moisture to preserve chemical stability.
3. Solubility considerations: As a small molecule, MK-677 is generally prepared in DMSO-based stock solutions for in vitro assay work, following standard small-molecule solubilization practices.
4. Data limitations: In vitro potency and binding data do not by themselves establish an in vivo or human safety or efficacy profile; findings from cell-based assays represent one piece of a larger pharmacological picture.
5. Batch verification: Without third-party testing, researchers cannot confirm that a given batch matches the expected identity and purity needed for reproducible assay results.
6. Analytical confirmation: Compound identity and purity are typically confirmed via HPLC and FTIR spectroscopy, which should be reflected in a lot-specific Certificate of Analysis.

Where do researchers source MK-677?

For laboratory work involving GHSR-1a pharmacology, researchers typically prioritize batches with independent third-party verification of identity and purity. BehemothLabz supplies MK-677 Ibutamoren Capsules, verified at ≥99% purity by HPLC analysis with a lot-specific Certificate of Analysis, alongside its published quality control and testing protocols detailing the verification process applied to every batch.

MK-677 (Ibutamoren) occupies a distinct place in GHSR-1a research: a non-peptide small molecule developed before the discovery of ghrelin itself, with nanomolar potency and affinity at the receptor, a roughly 24-hour half-life, and a stability profile that continues to make it a practical in vitro tool compound. Its role in characterizing GHSR-1a signalling, its continued use as a reference agonist in receptor pharmacology studies, and the safety signals documented in its clinical research history are all well recorded in the literature; though, as with any research compound, in vitro binding and functional data represent a starting point for investigation rather than a conclusion about safety or effect in any living system. For researchers working in this space, BehemothLabz offers COA-verified MK-677 for laboratory use.

FAQS

• What receptor does MK-677 act on? MK-677 is a selective, non-peptide agonist of the growth hormone secretagogue receptor (GHSR-1a), the same receptor later found to be the natural target of the peptide hormone ghrelin.
• Is MK-677 a peptide? No. Despite often being discussed alongside peptide-based growth hormone secretagogues, MK-677 is a non-peptide small molecule with a spiroindoline chemical structure, which is part of why it doesn’t share the same degradation profile as peptide ligands.
• What is MK-677’s potency and binding affinity at its target receptor? In the original in vitro characterisation, MK-677 released growth hormone from cultured rat pituitary cells with an EC50 of approximately 1.3 nM. Separately, radioligand binding studies have characterized its GHSR-1a binding affinity at a Ki of approximately 0.4 nM.
• Is MK-677 the same as a SARM? No. MK-677 is a growth hormone secretagogue acting on GHSR-1a, not a selective androgen receptor modulator. It does not bind androgen receptors.
• What is MK-677’s WADA status? MK-677 (ibutamoren) is prohibited at all times under the WADA Prohibited List, category S2.2 (Growth Hormone Secretagogues and Mimetics). It is banned both in-competition and out-of-competition, and any athlete subject to anti-doping testing should treat it as a prohibited substance.
• Where can researchers find verified MK-677 for laboratory use? Researchers typically source COA-verified batches from suppliers offering independent third-party testing, such as BehemothLabz’s MK-677 Ibutamoren Capsules, to confirm identity and purity before use in study design.

Robert Haynes, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.